Evotec's Summer of Setbacks Hardens Into a Stubborn Trading Range

Evotec's shares trade near 52-week low after H1 revenue fell 19.2% and EBITDA swung to a loss; analysts hold 'Hold' rating.

The arithmetic at Evotec is becoming difficult to ignore. Hamburg's drug discovery specialist has surrendered 41 percent of its market value since January, and with the shares hovering just above €3.20, the gap to the November peak of €7.75 now stands at roughly 59 percent. That kind of erosion does not happen by accident — it reflects a company that spent the summer walking back its own promises.

The most recent confirmation arrived with the half-year numbers, which locked in the guidance cut first announced in mid-July. Management has chosen to stand by that reduced target range for 2026 rather than revise it again, a decision that at least removes one layer of uncertainty. But the figures underneath are sobering: first-half revenue fell to €300.1 million, a 19.2 percent decline year-on-year, while adjusted EBITDA swung from a marginal minus €1.9 million to a far deeper minus €42.7 million.

Management points to the "Horizon" transformation program as the corrective mechanism, insisting it is running to plan and has already generated cost savings in the first six months. Investors, however, have heard that language before. What they are watching now is whether the operational bright spots can eventually outweigh the drag elsewhere.

Not Everything Is Bleeding

Sandwiched between the gloomy headline numbers are pockets of genuine momentum. The Discovery & Preclinical Development division posted net revenue growth of roughly 28 percent in the first half, while the Just–Evotec Biologics subsidiary reports strong capacity utilization and a broadening customer base. These are not trivial achievements, but they remain insufficient to offset the weakness at group level — a tension that defines the current investment case.

The stock's technical position tells a similar story of strain. At Friday's close of €3.23, down 0.6 percent on the day, the shares were trading just 3.0 percent above the 52-week low of €3.14 set on September 2. The distance to the 200-day moving average of €4.94 is even more telling: the price sits 35 percent below that benchmark, evidence of a downtrend that has been building for months rather than days. The RSI reading of 35.7 hints at oversold conditions, but technicians are reluctant to call a bottom without a fundamental catalyst to back it up.

A Disclosure That Raises More Questions Than Answers

Adding to the mix is a regulatory filing from Goldman Sachs disclosing a stake in the company. The notification is not new — it dates back some time — and no details have emerged regarding the size of the position or the strategic thinking behind it. Whether the bank is holding a trading position, hedging derivative exposure, or building a longer-term investment remains a matter of speculation. For shareholders, the ambiguity is frustrating: the filing offers no actionable insight, and its lack of fresh news value mirrors the broader information vacuum surrounding the company.

That vacuum has been filled with a series of unwelcome developments in recent weeks. Beyond the guidance reduction, Evotec has had to navigate the departure of supervisory board member Camilla Macapili Languille, who stepped down on August 7. The resignation coincided with reporting season, though the company has drawn no direct link between the exit and business performance. Research partnerships with Plectonic and Odyssey Therapeutics continue, but they have not generated the kind of momentum that moves a share price.

Analysts Hold Their Fire

The analyst community is not rushing to defend the stock. The consensus rating sits at "Hold," reflecting a wait-and-see posture that is unlikely to shift until Evotec demonstrates convincing operational progress. The lowered revenue and EBITDA outlook for the current fiscal year continues to weigh on estimates, even if it no longer functions as a fresh trigger for selling.

For investors, the calculus is straightforward but uncomfortable. The Goldman Sachs disclosure cannot support an investment decision on its own, and the technical picture offers little encouragement. What matters now is whether Evotec can translate its research collaborations and pipeline into visible results over the coming months — the only path, it seems, back to the credibility that the summer's events have eroded.